Masson Connan D, Findlay-Greene Fern, Sousa Filipa Henderson, Henderson Paul, Fraser Jennifer A, Barlow Peter G, Stevens Craig
School of Applied Sciences, Edinburgh Napier University, Sighthill Campus, Sighthill Court, Edinburgh, EH11 4BN, UK.
Centre for Discovery Brain Sciences and UK Dementia Research Institute, The University of Edinburgh, Edinburgh, EH16 4SB, UK.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4467-4478. doi: 10.1007/s00210-024-03563-0. Epub 2024 Nov 1.
Activating autophagy may be therapeutically beneficial, and we have previously shown that azathioprine (AZA), an immunomodulatory drug, induces autophagy. Here, we evaluated the induction of autophagy by the thiopurines AZA, mercaptopurine (6-MP) and thioguanine (6-TG) in THP-1 macrophages and investigated the mechanism of action in the context of this cellular process. The cytotoxicity of thiopurines was evaluated using an LDH assay. Induction of endogenous LC3 by thiopurines was evaluated using immunostaining. To confirm autophagy activation by thiopurines, a GFP-RFP-LC3 reporter plasmid was used to monitor the maturation of autophagosomes to autolysosomes. Induction of apoptosis by thiopurines was evaluated using Annexin V/PI staining, and ER stress was assessed via RT‒PCR analysis of XBP1 splicing. To gain insight into the mechanism of action of thiopurines, mTORC1 activity and eIF2α-S51 phosphorylation were evaluated by immunoblotting. Thiopurines were not cytotoxic to cells and induced strong time- and concentration-dependent autophagy. Thiopurines activate autophagy with complete progression through the pathway. Induction of autophagy by thiopurines occurred independently of apoptosis and ER stress. Immunoblotting revealed that AZA inhibited mTORC1 activity, and AZA and 6-TG increased eIF2α-S51 phosphorylation. In contrast, 6-MP had a minor effect on either signalling pathway. Thiopurines are strong inducers of autophagy, and autophagy induction should be considered among the mechanisms responsible for patient response to thiopurines.
激活自噬可能具有治疗益处,我们之前已经表明,免疫调节药物硫唑嘌呤(AZA)可诱导自噬。在此,我们评估了硫嘌呤类药物AZA、巯嘌呤(6-MP)和硫鸟嘌呤(6-TG)在THP-1巨噬细胞中对自噬的诱导作用,并在这一细胞过程的背景下研究了其作用机制。使用乳酸脱氢酶(LDH)测定法评估硫嘌呤类药物的细胞毒性。使用免疫染色评估硫嘌呤类药物对内源性LC3的诱导作用。为了证实硫嘌呤类药物激活自噬,使用GFP-RFP-LC3报告质粒来监测自噬体向自溶酶体的成熟过程。使用膜联蛋白V/碘化丙啶(Annexin V/PI)染色评估硫嘌呤类药物对细胞凋亡的诱导作用,并通过对XBP1剪接的逆转录-聚合酶链反应(RT-PCR)分析来评估内质网应激。为了深入了解硫嘌呤类药物的作用机制,通过免疫印迹法评估雷帕霉素靶蛋白复合体1(mTORC1)活性和真核翻译起始因子2α(eIF2α)丝氨酸51位点的磷酸化。硫嘌呤类药物对细胞无细胞毒性,并诱导强烈的时间和浓度依赖性自噬。硫嘌呤类药物通过该途径完全进展来激活自噬。硫嘌呤类药物诱导自噬的发生独立于细胞凋亡和内质网应激。免疫印迹显示,AZA抑制mTORC1活性,AZA和6-TG增加eIF2α丝氨酸51位点的磷酸化。相比之下,6-MP对这两种信号通路的影响较小。硫嘌呤类药物是自噬的强诱导剂,在患者对硫嘌呤类药物反应的机制中应考虑自噬诱导作用。